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Background: Narcolepsy is a neurologic disorder characterized by excessive daytime 
sleepiness, symptoms of abnormal rapid eye movement (REM) sleep, and a strong asso-
ciation with HLA-DRB1*1501, -DQA1*0102, and -DQB1*0602. Here, we investigated the 
clinico-physical characteristics of Korean patients with narcolepsy, their HLA types, and 
the clinical utility of high-resolution PCR with sequence-specific primers (PCR-SSP) as a 
simple typing method for identifying DRB1*15/16, DQA1, and DQB1 alleles. 
Methods: The study population consisted of 67 consecutively enrolled patients having un-
explained daytime sleepiness and diagnosed narcolepsy based on clinical and neurologi-
cal findings. Clinical data and the results of the multiple sleep latency test and polysom-
nography were reviewed, and HLA typing was performed using both high-resolution PCR-
SSP and sequence-based typing (SBT).
Results: The 44 narcolepsy patients with cataplexy displayed significantly higher frequen-
cies of DRB1*1501 (Pc=0.003), DQA1*0102 (Pc=0.001), and DQB1*0602 (Pc=0.014) 
than the patients without cataplexy. Among patients carrying DRB1*1501-DQB1*0602 or 
DQA1*0102, the frequencies of a mean REM sleep latency of less than 20 min in noctur-
nal polysomnography and clinical findings, including sleep paralysis and hypnagogic hal-
lucination were significantly higher. SBT and PCR-SSP showed 100% concordance for 
high-resolution typing of DRB1*15/16 alleles and DQA1 and DQB1 loci.
Conclusions: The clinical characteristics and somnographic findings of narcolepsy patients 
were associated with specific HLA alleles, including DRB1*1501, DQA1*0102, and DQB1* 
0602. Application of high-resolution PCR-SSP, a reliable and simple method, for both al-
lele- and locus-specific HLA typing of DRB1*15/16, DQA1, and DQB1 would be useful for 
characterizing clinical status among subjects with narcolepsy.
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INTRODUCTION
Narcolepsy is a neurologic disorder characterized by excessive 
daytime sleepiness and the clinical manifestations of abnormal 
rapid eye movement (REM) sleep such as cataplexy (sudden 
episodes of loss of postural muscle tone triggered by emotions). 
The close association between narcolepsy and HLA has been 
consistently reported in the literature. The HLA types that have 
been associated with narcolepsy include HLA-DQB1*0602, DQA1* 
0102, and DR2 [1-3]. Previous studies have shown the disorder Woo HI, et al.
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to be primarily associated with alleles of the linked DQ loci (i.e., 
DQB1*0602 and DQA1*0102), while DR2 association is a sec-
ondary effect [4, 5]. A higher prevalence of DQB1*0602 homo-
zygotes and a stronger correlation of this genotype with narco-
lepsy were observed in the Japanese compared to those in Afri-
can-Americans and white Americans [1]. DQB1*0602 has been 
shown to be closely associated with the presence of cataplexy. 
Previous studies have demonstrated that the presence of DQB1* 
0602 is reduced among patients in whom cataplexy is absent or 
ill defined [6, 7]. Differences in the frequency of certain HLA al-
leles have been observed in previous reports, and these differ-
ences have been suggested to be associated with ethnic origin 
and other factors, including the diagnostic criteria used to iden-
tify narcolepsy [2, 8, 9]. More specifically, the frequency and in-
fluence of DR2 has been reported to differ according to ethnic 
origin and the resolution of the HLA typing method. DRB1*1501 
has been shown to be a risk factor, while DRB1*1502 has been 
shown to be a protective factor against the development of nar-
colepsy [7]. 
  Based on these reports, it is becoming increasingly important 
to utilize high-resolution molecular techniques, such as sequence-
based typing (SBT), to determine HLA types at the allelic level in 
narcolepsy patients. SBT is a method that can identify all se-
quence variations as well as new polymorphisms. This method 
has been regarded as the standard method for HLA typing at 
the allelic level. However, SBT has several disadvantages, in-
cluding high equipment costs, time and labor intensiveness, the 
need for experts, perceived complexity, and occasional inaccu-
racy [10]. Low to intermediate resolution PCR-reverse sequence-
specific oligonucleotide hybridization (PCR-SSO) and PCR with 
sequence-specific primers (PCR-SSP) have been used for HLA 
typing at the serological level in clinical settings. These methods 
have replaced conventional cytotoxicity-based HLA typing meth-
ods; however, these methods has been applied to low to inter-
mediate resolution typing. PCR-SSP that includes more probes 
and primers for the targeted genes of interest, so called high-
resolution PCR-SSP, provides high resolution at the allelic level, 
a relatively short turn-around time, less complexity in both pro-
cess and interpretation, and requires fewer resources. There-
fore, high-resolution PCR-SSP could be a useful and practical 
method for the detection of a limited number of target alleles re-
lated to specific diseases, including narcolepsy.
  In this study, we aimed to make use of high-resolution PCR-
SSP to analyze the frequencies of DRB1, DQA1, and DQB1 poly-
morphisms among patients with narcolepsy in Korea and to in-
vestigate the association between HLA allele types and clinical 
features of the disorder, and thus, demonstrate the usefulness 
of this simple PCR-SSP method for the clinical assessment of 
narcolepsy patients.
METHODS
1. Patients and controls
The 67 consecutive Korean patients diagnosed with narcolepsy 
according to the results of clinical and neurological examinations 
at the sleep disorder clinic of Samsung Medical Center between 
July 2009 and January 2010 were enrolled in this study. Written 
informed consent was obtained from every patient or legal guard-
ian, and the study was approved by the Institutional Ethics Com-
mittee. Clinical data, including onset age, the presence or ab-
sence of cataplexy, associated features (e.g., sleep paralysis and 
hypnagogic hallucinations), and the results of the multiple sleep 
latency test (MSLT) and nocturnal polysomnography were re-
viewed. The results of polysomnography were available for 64 
patients, and the results of the MSLT were available for all 67 
subjects. The patients were categorized according to the Inter-
national Classification of Sleep Disorders (ICSD)-2 [11] into 2 
groups: (1) narcolepsy with cataplexy and (2) narcolepsy with-
out cataplexy but with a mean sleep latency of less than or equal 
to 8 min and the presence of 2 or more sleep-onset REM peri-
ods (SOREMPs) during the MSLT. High-resolution PCR-SSP was 
used to type the HLA-DRB1*15/16 and DQB1 alleles in all 67 
patients. Simultaneously, SBT was used to type the DRB1 and 
DQB1 alleles in all 67 patients. For DQA1, 34 patients were typed 
using only SBT, and 33 were typed using both PCR-SSP and SBT. 
  In order to compare the results in patients with narcolepsy 
with the results in the general population, the prevalence of 
HLA-DRB1, DQA1, and DQB1 was assessed among 467 ran-
domly selected control participants from previous studies per-
formed in Korea [12, 13].
2. DNA extraction 
Genomic DNA was extracted from 200 μL of an EDTA whole 
blood sample using a QuickGene DNA whole blood kit S and 
QuickGene-Mini80 (Fujifilm Corp., Tokyo, Japan) according to 
the manufacturer’s instructions. This extracted DNA was used 
for both high-resolution PCR-SSP and SBT. The concentration 
and purity of the DNA samples were measured as the optical 
density at 260 nm and the ratio of the optical densities at 260/ 
280 nm, respectively, using a NanoDrop (Thermo Fisher Scien-
tific, Wilmington, DE, USA). The required concentration and pu-
rity were 20-50 ng/μL and 1.7-1.9, respectively.Woo HI, et al.
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 3. SBT
To type DRB1 and DQB1, genomic DNA was amplified using 
SeCore
® Sequencing Kits (Invitrogen Corp., Madison, WI, USA). 
Master mix (20 μL) containing either DRB1- or DQB1-locus spe-
cific primers and FastStart™ Taq DNA polymerase (Roche Di-
agnostics Korea, Seoul, Korea) was added to the DNA sample (5 
μL). The same volume of master mix was added to 5 μL of de-
ionized water as a negative control. The DNA amplification was 
performed according to the program parameters in an ABI 9700 
thermal cycler (Applied Biosystems Inc., Foster City, CA, USA). 
After the primary amplification, the PCR products were sequenced 
using 3 separate sequencing primers for exon 2 of DRB1 (for-
ward, reverse, and codon 86), and 2 separate sequencing primer 
pairs for DQB1 (forward and reverse of both exon 2 and exon 3). 
After 25 cycles of the sequencing reaction, the DNA was puri-
fied, denatured, and sequenced using an ABI 3130 genetic ana-
lyzer (Applied Biosystems). Sequence data were analyzed using 
Assign-SBT
TM 3.5+ software (Conexio Genomics, Fremantle, 
Western Australia, Australia).
  Genotyping of the DQA1 locus was performed using the method 
previously described by Voorter et al. [14]. In total, 16 separate 
sequencing and amplification primers (forward and reverse of 
exons 1-4) were used. DNA amplification was performed in an 
ABI 9700 thermal cycler (Applied Biosystems). For the sequenc-
ing reactions, a solid phase sequencing approach was performed 
using an Autoread Sequencing kit (Amersham Biosciences, 
Roosendaal, Netherlands) according to the supplier’s protocol. 
Sequence data were analyzed using Pharmacia Typing Software 
(Pharmacia Biotech, Uppsala, Sweden).
4. High-resolution PCR-SSP
High-resolution PCR-SSP was performed using AllSet+
TM Gold 
SSP Typing Kits (Invitrogen Corp., Madison, Wi, USA). High-res-
olution PCR-SSP provided allelic-level genotyping of DRB1*15/16 
and locus-specific allelic-level genotyping of DQB1 and DQA1. A 
master mix containing dNTPs, gel loading buffer, and Taq DNA 
polymerase was added to the contamination control tube and 
the wells of the AllSet+
TM Gold SSP tray containing allele- and/or 
group-specific primers (23, 28, and 31 pairs for DRB1*15/16, 
DQA1 and DQB1, respectively) with a control primer pair match-
ing the non-allelic sequence. Genomic DNA (2 µL) was added to 
each well, and DNA amplification was performed according to 
the program parameters using an ABI 9700 thermal cycler. The 
PCR products were transferred to 1.8% agarose gels containing 
ethidium bromide, and electrophoresed for 10 min at 15 V/cm. 
The positive lanes were visually determined and analyzed using 
UniMatch Software 4.0 (Invitrogen Corp., Madison, Wi, USA).
5. Statistical analysis 
Data were analyzed by sorting patients according to the pres-
ence or absence of cataplexy, sleep paralysis, hypnagogic hallu-
cinations, the results of polysomnography and MSLT based on 
ICSD-1 and -2 criteria [11], and HLA types. Categorical variables 
were used for the frequency analysis. Significance testing was 
conducted using Fisher’s exact test for independence. P-values 
were corrected using the Bonferroni method (Pc) by multiplying 
the probability value by the number of alleles compared. P val-
ues less than 0.05 were considered statistically significant. The 
frequency and concordance for HLA alleles were compared for 
both the SBT and high-resolution PCR-SSP methods. The HLA-
DRB1*1501-DQA1*0102-DQB1*0602 haplotype, sleep paralysis, 
hypnagogic hallucinations, and a mean REM sleep latency less 
than 20 min and a mean sleep latency less than 5 min based on 
ICSD-1 and -2 criteria were included as confounding variables 
in the multiple logistic regression. Haplotypes were constructed 
by giving priority to combinations that showed higher associa-
tion in previously reported Korean data [15]. The test for Hardy-
Weinberg equilibrium (HWE) in control subjects was performed 
with a permutation test using SAS/Genetics version 9.1.3 (SAS 
Institute Inc., Cary, NC, USA).
RESULTS
1. The frequency of HLA phenotypes in patients with narcolepsy
Among the 67 patients, there were 51 males and 16 females. 
The median age of the subjects was 34.8 yr (range; 13-69 yr). Of 
the 67 patients, 44 (65.7%) were diagnosed to have narcolepsy 
with cataplexy, and 23 (34.3%) were diagnosed to have narco-
lepsy without cataplexy based on the ICSD-2 criteria. 
  Phenotype frequencies of HLA alleles in controls and narcolesy 
patients are shown in Table 1. HLA-DRB1*1501, DQA1*0102, 
and DQB1*0602 were present in 46 (68.7%), 48 (71.6%), and 
46 (68.7%) patients with narcolepsy, respectively, regardless of 
having cataplexy. All patients with DRB1*1501 were also typed 
as DQB1*0602, and DRB1*1501 and DQB1*0602 were more 
frequently detected in patients with cataplexy than in patients 
without cataplexy (86.4% vs. 34.8%, Pc=0.003 for DRB1*1501 
and Pc=0.001 for DQB1*0602). The frequency of DQA1*0102 
was also significantly higher in patients with cataplexy than in 
patients without cataplexy (86.4% vs. 43.5%, Pc=0.014). In 
healthy controls, the frequencies of DRB1*1501 (14.8%) and 
DQB1*0602 (14.1%) were significantly lower than the frequen-Woo HI, et al.
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Table 1. Phenotype frequencies of HLA class II alleles in controls and narcolepsy patients with or without cataplexy
Control*, N=467 Narcolepsy with cataplexy, N=44 Narcolepsy without cataplexy, N=23
N (%)  N (%) Pc-value
† OR
† (95% CI)  N (%) Pc-value
‡ OR
‡ (95% CI)
DRB1*0101  58 (12.4)  1 (2.3)  2 (8.7)
DRB1*0301 28 (6.0)  2 (4.5)  1 (4.3)
DRB1*0401  7 (1.5) 0 (0)  1 (4.3)
DRB1*0403 29 (6.2)  1 (2.3)  1 (4.3)
DRB1*0404 19 (4.1) 0 (0)  1 (4.3)
DRB1*0405  81 (17.3)  3 (6.8)   3 (13.0)
DRB1*0406 38 (8.1)  2 (4.5)  1 (4.3)
DRB1*0407  6 (1.3)  1 (2.3) 0 (0)
DRB1*0408  1 (0.2) 0 (0)  1 (4.3)
DRB1*0410 12 (2.6)  1 (2.3) 0 (0)
DRB1*0701  62 (13.3)  2 (4.5)   3 (13.0)
DRB1*0802 18 (3.9) 0 (0)  2 (8.7)
DRB1*0803  73 (15.6)  2 (4.5)   4 (17.4)
DRB1*0901  83 (17.8)   6 (13.6)  2 (8.7)
DRB1*1001 14 (3.0) 0 (0) 0 (0)
DRB1*1101 41 (8.8)  2 (4.5)  1 (4.3)
DRB1*1106  1 (0.2) 0 (0) 0 (0)
DRB1*1201 30 (6.4)   5 (11.4)   4 (17.4)
DRB1*1202 30 (6.4)  3 (6.8)  1 (4.3)
DRB1*1205 0 (0)  1 (2.3) 0 (0)
DRB1*1301  9 (1.9) 0 (0)  1 (4.3)
DRB1*1302  78 (16.7)   6 (13.6)  2 (8.7)
DRB1*1307 0 (0)  1 (2.3) 0 (0)
DRB1*1401 28 (6.0)  3 (6.8)  1 (4.3)
DRB1*1404 0 (0)  1 (2.3) 0 (0)
DRB1*1405 32 (6.9) 0 (0)  1 (4.3)
DRB1*1406  7 (1.5) 0 (0) 0 (0)
DRB1*1407  2 (0.4) 0 (0)  1 (4.3)
DRB1*1410  2 (0.4) 0 (0) 0 (0)
DRB1*1412  2 (0.4) 0 (0) 0 (0)
DRB1*1501  69 (14.8)  38 (86.4) <0.001 36.5 (7.7-332.6)   8 (34.8) 0.003 11.9 (1.2-173.8)
DRB1*1502 32 (6.9)  2 (4.5)  2 (8.7)
DRB1*1602  6 (1.3)  1 (2.3) 0 (0)
DQA1*0101  63 (13.5)  1 (2.3)  2 (8.7)
DQA1*0102 142 (30.4)  38 (86.4) <0.001 14.5 (3.4-114.0)  10 (43.5) 0.014 8.2 (1.0-98.8)
DQA1*0103  94 (20.3)  4 (9.1)   6 (26.1)
DQA1*0104  58 (12.4)  4 (9.1)   3 (13.0)
DQA1*0105 14 (3.0) 0 (0) 0 (0)
DQA1*0201  62 (13.3)  2 (4.5)   3 (13.0)
DQA1*0301  85 (18.2)  4 (9.1)   3 (13.0)
(Continued to the next page)Woo HI, et al.
Use of PCR-SSP HLA typing in narcolepsy
61 http://dx.doi.org/10.3343/alm.2012.32.1.57 www.annlabmed.org
cies among narcolepsy patients with cataplexy (both, Pc<0.001). 
DQA1*0102 was detected in 30.4% of the controls, which was 
also significantly lower than the percentage observed in narco-
lepsy patients with cataplexy (Pc<0.001). Compared with the 
control group, higher frequencies of DRB1*1501, DQA1*0102, 
and DRB1*0602 were observed among narcolepsy patients 
without cataplexy; however, this effect did not reach statistical 
significance. In addition, differences in the frequencies of all 
other alleles except DRB1*1501, DQB1*0602, and DQA1*0102 
were also observed among the groups; however, none of these 
differences reached statistical significance between the controls 
and narcolepsy patients with or without cataplexy (Table 1).
  All individuals who were homozygous for DRB1*1501 or DQB1* 
0602 were DRB1*1501-DQB1*0602 homozygotes, and all DRB1* 
1501-DQB1*0602 homozygotes were also DQA1*0102 homozy-
gotes. There were 5 patients (7.5%) who were homozygous for 
both DRB1*1501 and DQB1*0602, and 4 of these patients (80%) 
had cataplexy. There were 13 patients (19.4%) who were homo-
zygous for DQA1*0102, and these patients also had cataplexy 
more frequently than DQA1*0102 heterozygotes, although this 
difference did not reach statistical significance (25.0% vs. 8.7%, 
P=0.191). Only 2 control individuals (0.4%) were DRB1*1501-
DQA1*0102-DQB1*0602 homozygotes.
  In the 69 control subjects with DRB1*1501-DQA1*0102-DQB1* 
Table 1. (Continued from the previous page) Phenotype frequencies of HLA class II alleles in controls and narcolepsy patients with or without cat-
aplexy
Control*, N=467 Narcolepsy with cataplexy, N=44 Narcolepsy without cataplexy, N=23
N (%)  N (%) Pc-value
† OR
† (95% CI)  N (%) Pc-value
‡ OR
‡ (95% CI)
DQA1*0302  93 (19.9)   6 (13.6)   3 (13.0)
DQA1*0303 110 (23.6)  4 (9.1)   5 (21.7)
DQA1*0401 15 (3.2)  1 (2.3)  2 (8.7)
DQA1*0501 28 (6.0)  2 (4.5)  1 (4.3)
DQA1*0503 11 (2.4)  1 (2.3) 0 (0)
DQA1*0505  55 (11.8)   6 (13.6)  2 (8.7)
DQA1*0506  1 (0.2)  1 (2.3)  1 (4.3)
DQA1*0507  6 (1.3) 0 (0) 0 (0)
DQA1*0508  7 (1.5) 0 (0)  1 (4.3)
DQA1*0601 40 (8.6)  3 (6.8)  1 (4.3)
DQB1*0201 28 (6.0)  2 (4.5)  1 (4.3)
DQB1*0202  57 (12.2)  2 (4.5)   3 (13.0)
DQB1*0301 116 (24.8)  11 (25.0)   7 (30.4)
DQB1*0302  92 (19.7)  4 (9.1)   4 (17.4)
DQB1*0303  99 (21.2)   6 (13.6)   3 (13.0)
DQB1*0401  78 (16.7)  3 (6.8)   3 (13.0)
DQB1*0402 34 (7.3)  2 (4.5)  2 (8.7)
DQB1*0501  75 (16.1)  1 (2.3)  2 (8.7)
DQB1*0502 21 (4.5)  2 (4.5)  1 (4.3)
DQB1*0503 44 (9.4)  3 (6.8)  2 (8.7)
DQB1*0601  87 (18.6)  4 (9.1)   6 (26.1)
DQB1*0602  66 (14.1)  38 (86.4) <0.001 38.5 (8.8-300.6)   8 (34.8) 0.001 11.9 (1.4-146.6)
DQB1*0603  9 (1.9) 0 (0) 0 (0)
DQB1*0604 45 (9.6)  3 (6.8)  2 (8.7)
DQB1*0609 35 (7.5)  3 (6.8)  1 (4.3)
Pc-values greater than 0.05 are not displayed.
*The control data were obtained from previously published studies in Korea [12-13]; 
†Pc-value and OR from comparison of narcolepsy with cataplexy group 
to the control group; 
‡Pc-value and OR from comparison of narcolepsy with cataplexy group to narcolepsy without cataplexy group.
Abbreviations: OR, odds ratio; Pc-value, Bonferroni corrected P value.Woo HI, et al.
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Table 2. Demographic, clinical, and somnographic characteristics of narcolepsy patients according to the presence of cataplexy
Narcolepsy with cataplexy Narcolepsy without cataplexy P value
† OR (95% CI)
† OR (95% CI)
‡
Total, N (%) 44 (65.7) 23 (34.3)
Age, median (range), yr 29 (13-69) 37 (18-62) 0.668 1.01 (0.97-1.04)
M : F ratio 32:12 19:4 0.548 0.56 (0.16-1.99)
Age of onset <20 yr, N (%) 29 (65.9) 14/17 (82.4)* 0.348 2.41 (0.60-9.73)
Clinical features
  Sleep paralysis, N (%) 28 (63.6) 7 (30.4) 0.010 4.00 (1.36-11.78) 1.68 (0.44-6.45)
  Hypnagogic hallucinations, N (%) 23 (52.3) 2 (8.7) <0.001 11.50 (2.40-55.08) 5.02 (0.87-29.00)
Nocturnal polysomnography
  Sleep latency <10 min 40 (90.9) 20 (87.0) 0.684 1.50 (0.31-7.36)
  Mean REM sleep latency <20 min 32 (72.7) 8/20 (40.0) 0.024 5.00 (1.69-14.79) 2.12 (0.54-8.28)
Multiple sleep latency test
  MSL <5 min 40 (90.9) 17 (73.9) 0.080 3.53 (0.88-14.12) 1.55 (0.29-8.36)
  MSL ≤8 min 43 (97.7) 21 (91.3) 0.269 4.10 (0.35-47.77)
  SOREMP ≥2 times 42 (95.5) 23 (100) 0.542 -
HLA haplotype
  DRB1*1501-DQA1*0102-DQB1*0602 38 (86.4) 8 (34.8) <0.001 11.88 (3.52-40.05) 4.74 (1.14-19.81)
§
*Age of onset in narcolepsy without cataplexy patient group was available for only 17 patients; 
†Univariate analysis; 
‡Multivariate analysis, analyzed with sleep 
paralysis, hypnagogic hallucinations, a mean REM sleep latency less than 20 min, a mean sleep latency less than 5 min according to ICSD-1 and -2 diag-
nostic criteria, and the DRB1*1501-DQA1*0102-DQB1*0602 haplotype; 
§In multivariate analysis, only the HLA-DRB1* 1501- DQA1*0102-DQB1*0602 
haplotype had statistical significance (P=0.033).
Abbreviations: OR, odds ratio; CI, confidence interval; REM, rapid eye movement; MSL, mean sleep latency; SOREMP, sleep-onset REM periods.
0602, there were 26 heterozygous haplotypes carried in trans of 
DRB1*1501-DQA1*0102-DQB1*0602. When we compared the 
haplotype combinations of all alleles carried in trans of DRB1* 
1501-DQA1*0102-DQB1*0602 in the control subjects with those 
in the 46 patients according to the presence or absence of cata-
plexy, there were 25 haplotypes with frequencies of 2.2-10.9%. 
However, no statistically significant differences in haplotype fre-
quency were observed between the controls and patients with 
narcolepsy, and between patient groups with or without cata-
plexy (data not shown). There was no significant difference from 
HWE at any locus in the 467 randomly selected controls (P= 
0.310 for DRB1; P=0.337 for DQA1; P=0.162 for DQB1).
2.     High-resolution molecular typing of narcolepsy-associated 
HLA alleles
There were no discordant results observed in the DRB1*15/*16 
and DQB1 typing of the 67 patients and the DQA1 typing of 33 
patients using the SBT and high-resolution PCR-SSP methods. 
Using the high-resolution PCR-SSP technique, DRB1*1501, 
DRB1*1502, and DRB1*1602 alleles were easily distinguished 
according to their band patterns. A total of 14 DQB1 and 15 
DQA1 alleles, including DQB1*0602 and DQA1*0102, which have 
been shown to be associated with narcolepsy, were correctly 
identified. During an initial interpretation, one SBT and one PCR-
SSP result for DQA1 were incorrectly assigned; however, these 
initial assignments were corrected after a final interpretation. In 
one case, DQA1*0401 was assigned as DQA1*0102 during the 
initial reading because a weak positive band was ignored in the 
PCR-SSP. The other was an incorrect assignment of DQA1*0506 
as DQA1*0503, due to an overlapped peak not recognized in 
the SBT. In addition to the comparable performance of PCR-
SSP and SBT, the PCR-SSP method saved not only significant 
time, since the testing time is less than 3 hr compared to more 
than 6 hr for the SBT method, but also resources, such as an 
expensive sequencing analyzer and labor for testing and inter-
pretation.
3.     Clinico-physical and somnographic characteristics of nar-
colepsy patients
Sleep paralysis and hypnagogic hallucinations were observed in 
52.2% and 37.3% of patients, respectively. The frequencies of 
sleep paralysis and hypnagogic hallucinations were significantly 
higher among patients with cataplexy than among patients with-
out cataplexy (63.6% vs. 30.4%, P=0.010 for sleep paralysis; Woo HI, et al.
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52.3% vs. 8.7%, P<0.001 for hypnagogic hallucinations, Table 
2). The difference in the frequency of a mean REM sleep latency 
less than 20 min between patients with and without cataplexy 
was statistically significant (72.7% vs. 40.0%, P=0.024). In mul-
tivariable analyses, only the HLA-DRB1*1501-DQA1*0102-
DQB1*0602 haplotype still maintained statistical significance 
(P=0.033).
  A majority of the subjects (70.5%) had onset of disorder be-
fore adolescence. Although the frequency of cataplexy was 
lower, and the frequencies of sleep paralysis and hypnagogic 
hallucinations were slightly higher among patients with onset 
before adolescence, these differences did not reach statistical 
significance (67.4% vs. 83.3%, P=0.207 for cataplexy; 58.1% 
vs. 50.0%, P =0.559 for sleep paralysis; 44.2% vs. 33.3%, 
P=0.432 for hypnagogic hallucinations). The frequencies of 
polysomnography and the MLST diagnostic criteria were similar 
across groups (data not shown). 
  In the context of HLA type, the frequency of sleep paralysis 
and hypnagogic hallucinations was significantly higher among 
patients with DRB1*1501-DQB1*0602, (63.0% vs. 28.6%, P=
0.017 for sleep paralysis; 50.0% vs. 9.5%, P=0.002 for hypna-
gogic hallucinations; Table 3). Similar results were observed 
among patients typed as DQA1*0102 (62.5% vs. 26.3%, P=0.014 
for sleep paralysis; 47.9% vs. 10.5%, P=0.005 for hypnagogic 
hallucinations). According to the polysomnography findings, a 
mean REM sleep latency of less than 20 min was observed 
more frequently among DRB1*1501-DQB1*0602 (77.8% vs. 
26.3%, P<0.001) and DQA1*0102 (74.5% vs. 29.4%, P=0.003) 
positive patients than among negative patients; furthermore, 
DQA1*0102 was associated with a mean sleep latency of less 
than 5 min (91.7% vs. 68.4%, P=0.025). 
DISCUSSION
HLA-DRB1*15/*16, DQA1, and DQB1 typing was performed in 
narcolepsy patients using both the SBT and high-resolution 
PCR-SSP methods. The SBT method is used for the identifica-
tion of sequence variations, as well as the direct detection of 
new polymorphisms [16]. However, this method is demanding 
in terms of the resources, technique, time, and labor required. 
PCR-SSP is a powerful method for detecting genetic variability, 
including single base pair mismatches. It is a relatively quick 
and easy technique, and the post-amplification processing is 
simple, rapid, and consists only of determining whether amplifi-
cation has occurred [17, 18]. Additionally, HLA typing using 
PCR-SSP has been shown to be a relatively easy method with a 
higher detection rate than both PCR-SSO and PCR-restriction 
fragment length polymorphism (PCR-RFLP) methods [16-18]. 
Furthermore, when the PCR-SSP method was used, the results 
of the HLA typing were quickly obtained at a relatively low cost. 
In this study, when comparing the results using the high-resolu-
tion PCR-SSP and SBT methods, there were no discordant re-
sults observed for the typing of DRB1*15/*16, DQA1, and DQB1. 
However, there were potential errors in both methods during the 
interpretation process. The weak intensity of the positive bands 
in the PCR-SSP method, and the small or overlapped peaks in 
Table 3. Demographic, clinical, and somnographic characteristics of narcolepsy patients according to HLA types
DRB1*1501* DQA1*0102
Pos Neg P value OR (95% CI) Pos Neg P value OR (95% CI)
Total, N (%) 46 (68.7) 21 (31.3) 48 (71.6) 19 (28.4)
M : F ratio 34 : 12 17 : 4 0.758 0.67 (0.19-2.38) 35 : 13 16 : 3 0.526 0.51 (0.13-2.02)
Clinical features
  Sleep paralysis, N (%) 29 (63.0) 6 (28.6) 0.017 4.27 (1.39-13.07) 30 (62.5) 5 (26.3) 0.014 4.67 (1.44-15.13)
  Hypnagogic hallucinations, N (%) 23 (50.0) 2 (9.5) 0.002 9.50 (1.98-45.55) 23 (47.9) 2 (10.5) 0.005 7.82 (1.63-37.62)
Nocturnal polysomnography
  Sleep latency <10 min
42 (91.3) 18 (85.7) 0.669 1.75 (0.36-8.63) 44 (91.7) 16 (84.2) 0.395 2.06 (0.42-10.24)
  Mean REM sleep latency <20 min 35/45 (77.8) 5/19 (26.3) <0.001 10.18 (3.03-34.19) 35/47 (74.5) 5/17 (29.4) 0.003 7.54 (2.26-25.11)
Multiple sleep latency test MSL <5 min 42 (91.3) 15 (71.4) 0.060 4.20 (1.04-16.96) 44 (91.7) 13 (68.4) 0.025 5.08 (1.24-20.76)
  MSL ≤8 min 45 (97.8) 19 (90.5) 0.229 4.74 (0.41-55.42) 47 (97.9) 17 (89.5) 0.192 5.53 (0.47-64.96)
  SOREMP ≥2 times 45 (97.8) 20 (95.2) 0.532 2.25 (0.13-37.80) 47 (97.9) 18 (94.7) 0.490 2.61 (0.16-44.01)
*Identical to DQB1*0602, that is, all individuals were DRB1*1501-DQB1*0602.
Abbreviations: Pos, positive; Neg, negative; OR, odds ratio; CI, confidence interval; REM, rapid eye movement; MSL, mean sleep latency; SOREMP, sleep-
onset REM periods.Woo HI, et al.
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the SBT method could result in the incorrect assignment of HLA 
types. However, in nearly all cases, the exclusion of the weak 
band during the interpretation of PCR-SSP could result in correct 
HLA types; thus, it was possible to avoid misinterpretation. Both 
of the initial misinterpretations that occurred in this study were 
made in DQA1 typing, which generally requires the sequencing 
of more exons than most of the other HLA class II types in order 
to distinguish alleles [13, 14]. Therefore, extra caution seems to 
be required for DQA1 typing. Additionally, high-resolution PCR-
SSP cannot detect new alleles or alleles not provided by manu-
facturer. Therefore, the application of the high-resolution PCR-
SSP would be appropriate for testing of certain HLA types known 
to be related to a specific disease, but not for general use (e.g., 
HLA typing for transplantation).
  This study provides additional population data that confirms 
the association of the HLA-DRB1*1501, DQA1*0102, and DQB1* 
0602 alleles with narcolepsy and cataplexy among Korean pa-
tients [8, 10]. In previous reports, DRB1*1501-DQB1*0602 and 
DQA1*0102-DQB1*0602 have been shown to display a high de-
gree of linkage disequilibrium in the Korean population [12, 13, 
15]. There were some observed differences in the frequency of 
DRB1*1501, DQA1*0102, and DQB1*0602 among previous 
studies on narcolepsy patients [2, 8, 9]. These differences have 
been proposed to be due to differences in the diagnostic crite-
ria, including the presence of cataplexy, the ethnic origin of the 
patient groups, and the resolution of the HLA-typing method [2, 
19-21]. Even the frequency of DQB1*0602 in Korean narcoleptic 
patients with cataplexy from previous reports and this study var-
ied from 86.4% to 100% [9]. The relatively lower frequencies of 
DRB1*1501 and DQB1*0602 observed in this study compared 
to that observed by Hong et al. [8] and Roh et al. [9] might be 
due to the differences in conducting the polysomnography and 
the MLST or distinguishing between atypical and typical cata-
plexy. 
  Among Japanese subjects, it was determined that a signifi-
cant proportion of patients with narcolepsy were typed as DRB1* 
1501-DQA1*0102-DQB1*0602 homozygotes (15.2% of the pa-
tients). Other HLA types were also suggested as being associ-
ated with narcolepsy, DQB1*0301 as a susceptibility allele, and 
DQB1*0601/DQB1*0602 and DQB1*0601/DQB1*0501 heterozy-
gotes as having protective effects [1, 8]. In addition, the DQB1* 
0602 homozygote had a 2- to 4-fold increased risk of developing 
narcolepsy with cataplexy when compared to the heterozygote. 
In this study, 5 patients (7.5%) were DRB1*1501-DQA1*0102-
DQB1*0602 homozygotes, and among these patients, 4 pre-
sented with cataplexy. Heterozygous DQB1*0601/DQB1*0602 
and DQB1*0601/DQB1*0501 were detected in only a few pa-
tients (3 and 1 patients, respectively); therefore, we could not 
assess the clinical significance. A total of 18 patients (26.9%) 
had DQB1*0301, which was similar to the previously reported 
frecuency in Korean patients (27.8%); and this proportion was 
relatively high compared to that observed among Japanese, Eu-
ropean-American, and African-American patients (10% to 
14.9%) [1, 8]. However, there was no significant difference ob-
served in the frequency of DQB1*0301 between the control and 
patient groups. With the exception of the DRB1*1501, DQB1* 
0602, and DQA1*0102, no significant differences in the fre-
quency of other HLA alleles were observed between the patient 
and control groups, or among the patients according to the 
presence or absence of cataplexy.
  Previous research conducted in Korea by Hong et al. revealed   
significant differences in DQA1*0303 and DQB1*0301 as sus-
ceptibility alleles, and in DQA1*0103 and DQB1*0601 as protec-
tive alleles in the context of a DQA1*0102 or DQB1*0602 bearing 
haplotype [8]. In our study, we compared the haplotype combi-
nations for all alleles carried in trans of DRB1*1501-DQA1*0102-
DQB1*0602 in the control subjects and narcolepsy patients. 
However, the differences in the frequencies did not reach statis-
tical significance. Therefore, additional large-scale studies would 
be needed in order to evaluate the difference in the haplotype 
distribution according to the presence or absence of cataplexy.
  Sleep paralysis and hypnagogic hallucinations were frequently 
observed among narcolepsy patients with cataplexy, and a sig-
nificant number of these patients had DRB1*1501, DQA1*0102, 
and DQB1*0602. However, we could not confirm the significance 
of these findings in a multivariate analysis between the presence 
or absence of cataplexy and other categorized variables. The 
clinical features associated with narcolepsy, such as sleep pa-
ralysis and hypnagogic hallucinations, have been considered to 
have low diagnostic value. These criteria was removed from the 
ICSD-2 diagnostic criteria due to insufficient specificity for nar-
colepsy [11, 23]. Previous studies have shown that the fre-
quency of hypnagogic hallucinations and sleep paralysis does 
not appear to differ significantly between patients with and with-
out cataplexy [20, 22, 24]. In this study, a mean REM sleep la-
tency of less than 20 min in nocturnal polysomnography was 
frequently observed among narcolepsy patients with DRB1*1501, 
DQA1*0102, and DQB1*0602, and a mean sleep latency of less 
than 5 min in the MLST was frequently observed in patients with 
DQA1*0102. Watson et al. has reported the associations between 
somnographic findings and DQB1*0602 [22]. They showed that 
sleep latency was significantly shorter in patients with DQB1* Woo HI, et al.
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0602 than in patients without DQB1*0602 but did not evaluate 
mean REM sleep latency. In this study, we categorized and ana-
lyzed the somnographic findings according to ICSD-1 and -2 
criteria, whereas in the previous study these were analyzed as 
continuous variables. Although we considered that differences 
in sleep latency may exist between patients with and without 
DRB1*1501, DQA1*0102, and DQB1* 0602, this study might be 
not sufficient to confirm the significance of these differences due 
to limitation in number of patients. The relationship of HLA al-
leles with clinical and somnographic findings in narcolepsy pa-
tients should be confirmed through further studies.
  In summary, this study confirmed the association between 
specific HLA alleles and narcolepsy among Korean patients us-
ing both the high-resolution PCR-SSP and SBT methods. Differ-
ences in the clinical and somnographic findings according to 
the presence of particular HLA alleles, as well as the presence 
or absence of cataplexy, were shown. In addition to the high 
level of concordance with SBT methods for identifying DRB1* 
15/16, DQA1, and DQB1 alleles, the high-resolution PCR-SSP 
was simple and cost-effective method for the testing of HLA-
DRB1, -DQA1, and -DQB1 alleles known to be related with nar-
colepsy.
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